Kornimate/medical-research-clean huggingface dataset:
clinical validation study for edit-b test: an aid for differential diagnosis of bipolar disorder, based on rna editing blood biomarkers

Conditions: Bipolar Disorder; Major Depressive Disorder

Summary: differentiation between major depressive disorder (mdd) and bipolar disorder (bd) as soon as possible in the patient journey represents a major clinical issue. when the patient is in a depressive phase, the symptoms are similar between the two pathologies and the current clinical scales fail in distinguishing them. physicians often report this difficulty and as a consequence, the mean time from onset to bipolar disorder diagnosis is currently 7.5 years. these diagnostic delays and misdiagnosis lead to damaging consequences for patients and their loved ones: worsening of symptoms, comorbidities, suicide risk and inadequate care resulting in severe impairment in social and occupational functioning. faced with these high expectations for accurate diagnostic methods for an earlier management of psychiatric patients, the combination of relevant clinical features and biomarkers could stand for a solution, leading to a personalised approach in patients with mood disorders. in a first clinical discovery study, a panel of rna biomarkers in the blood of patients with a major depressive episode (mde) has been identified, allowing to differentiate bipolar disorder from mdd (unipolar depression). these biomarkers are based on rna modifications, namely rna editing, that could be identified using molecular biology, ngs and artificial intelligence. this panel constitutes edit-b test, which is based on alcediag's proprietary and patented biomarkers and algorithms. the present study aims to validate the biomarker signatures proposed by alcediag by measuring the association between the modifications of the rna editing and major depressive disorder/ bipolar disorder diagnosis, in patients with a mde in real-life setting pilot centres.


Eligibility criteria:
inclusion criteria: 1. signed informed consent. 2. male or female ≥ 18 and ≤ 80 years of age at inclusion. 3. madrs ≥ 20 4. in- and out-patients can be recruited. 5. diagnosed with mde with the mini for dsm-5 6. currently treated for the mde 7. diagnosed with mdd or bd with the mini for dsm-5. 8. for patients with bd: at least one manic or hypomanic episode 9. for patients with mdd: at least one mde exclusion criteria: 1. mdd patients with first degree family history of bipolar disorder 2. ymrs \> 12 3. pregnant women 4. unipolar or bipolar depression secondary to major central nervous system affections, including infections in the brain, tumours of the brain, stroke, alzheimer's disease, parkinson's disease, multiple sclerosis, other major brain affections 5. schizo-affective patients abbrevations: bd bipolar disorder dsm-5 diagnostic and statistical manual of mental disorders 5 madrs montgomery-asberg depression rating scale mdd major depressive disorder mde major depressive episode mini mini-international neuropsychiatric interview ymrs young mania rating scale
prevalence of sexually transmitted infections (stis) into prison in reunion

Conditions: Sexually Transmitted Diseases

Summary: since the beginning of the 2000s, there has been a steady increase in the incidence of stis in france. in reunion, the few figures available seem to show the same phenomenon, especially for syphilis. the unfavorable socio-economic context, which is characterized by high levels of precariousness, significant population exchanges (immigration, travel) with neighboring countries, behaviors around sexuality or screening for stis different from those observed in mainland france are all factors testify to the singularity of the reunion island in relation to the metropolitan france with regard to the risk factors of stis. sti management has become a priority in public health; in particular, the 2010-2014 hiv and sti control plan emphasized the need for their surveillance and screening. these are often asymptomatic infections that can cause serious complications if they are not treated (infertility, ectopic pregnancies, maternal-fetal infections, ...). screening them in at-risk populations is therefore essential to reduce their prevalence. the prison population is a vulnerable population, possibly exposed during the incarceration but also upstream of it (generally low levels of education, over-represented disadvantaged social categories, low access and use of care, high prevalence of risky behaviors). ). some prevalence studies of stis in these populations have been carried out in metropolitan france, indicating a prevalence higher than that observed in the general population. there is little data on the subject for the prison population in réunion; given the local specificities, it seems necessary to improve the epidemiological knowledge of stis in this prison population in réunion, in order to be able to adapt the prevention and care measures, the conditions of detention presenting potentially aggravating situations (promiscuity, confinement). , hygienic conditions, ...).


Eligibility criteria:
inclusion criteria: * imprisoned at domenjod prison between 01/02/2018 and on 04/30/2019 * able to answer a questionnaire, * domiciled in réunion at the time of incarceration, * incarceration medical examination carried out within 7 days incarceration, exclusion criteria: * incarcerated by transfer from another penal institution * having had antibiotic therapy in the 3 months before the inclusion consultation.
comparative study between retained and non-retained urinary catheter in total knee arthorplasty with epidural anesthesia

Conditions: Postoperative Urinary Retention; Urinary Tract Infections; Epidural Anesthesia

Summary: the purpose of this study is to compare the prevalence of postoperative urinary retention between retained and non-retained urinary catheter in total knee arthorplasty with epidural anesthesia


Eligibility criteria:
inclusion criteria: * primary osteoarthritis of knee who were scheduled for a primary total knee arthroplasty exclusion criteria: * history of renal disease * history of urinary tract infection * history of previous urinary tract surgery * benign prostatic hypertrophy * bilateral total knee arthroplasty * revision total knee arthroplasty * patients who need intraoperative monitoring of urine output
effectiveness of a schema therapy on anxiety in patients with multiple sclerosis

Conditions: Anxiety

Summary: it is a multicentric randomized and controlled study comparing a scheme therapy program versus local practice in rrms patients with anxiety. patients will assist to twenty once-weekly group sessions with a 6-month follow up after the end of the programme. the main criteria is the impact of schema therapy on anxiety evaluated by the questionnaires at the end of the program and at the end of the 6-month follow-up.

a parallel arm randomized controlled trial comparing a group receiving scheme therapy plus current usual practice versus a group receiving current local practice only. the trial will take place in kashani hospital (in isfahan).recruitment of the participants will be identified and recruited by the neurologists of the hospitals who take part in the programme, when they come for a medical examination. after giving their informed consent, the patients will be entered onto the trial database and randomized to either the schema therapy or control using software allocated the intervention is the schema therapy focuses on the management of anxiety and is based on self-efficacy, self-management . it consists of 20 once-weekly sessions of 90 minutes (with a 15 min break), with homework activities between the sessions. it is designed for groups of 8 people and will be delivered by two psychologists. the programme is standardized: power points presentations support each session and a detailed therapist manual and companion patient workbook accompany the programme. for the st group an evaluation will be administered pretest and post-test six months after the end of the schema therapy programme and at the same times for those in the control group. socio-demographic and medical data, age, sex, level of education, marital status, number of children and professional status; date of diagnosis, disease type, level of disability (edss, kurtzke, 1983) and information on relapses and treatments, are evaluated. the main criteria is the impact of schema therapy on anxiety evaluated by the bai (beck anxiety inventory ) and level of cortisol at 6 month after the start program . secondary criteria are: impact on the psychological dimensions assessed by hospital anxiety and depression scale (hads), intensity of fatigue assessed by fatigue severity scale (fss), sleep quality evaluated by the pittsburgh sleep quality index(psqi) depression by bdi (beck depression inventory ) and quality of life evaluated by (multiple sclerosis impact scale) msis29.

Eligibility criteria:
inclusion criteria: * subject has relapsing remitting ms * anxiety (score \>26 at the bai scale) * history of psychotic disorders * history of cognitive deficiency * use anti-depressant in the past 3 months * history of relapse in the past 3 month * expanded disability status scale score less than 6 * ability reading and writing persian * non hospitalized exclusion criteria: * history of psychotic disorders * history of cognitive deficiency * use anti-depressant in the past 3 months * history of relapse in the past 3 month

Keywords: anxiety multiple sclerosis schema therapy
immune response after leptospirosis infection

Conditions: Leptospirosis

Summary: leptospirosis is a zoonotic infection induced by pathogen bacteria (genus: leptospira) growing in water polluted by animal fluids. due to its 10 fold occurence in french overseas aera, and especially in reunion island, as compared to metropoly, it is considered as a major public health issue. an important inter-individual variability in humoral immune response suggests that vaccination should be recommended in exposed subjects. this cohort study aimed to determine if subjects that have been infected by leptospirosis for 1 to 7 years still remain immunized, and then do not need vaccination.

every year more than 500 000 severe forms of leptospirosis are diagnosed in reunion island. the risk of mucocutaneous contact with contaminated media remains important due to highly aqueous environment. cured subjects that have been infected for 1, 2, 3, 4, 5, 6 or 7 years will be enrolled. the qualitative and quantitative humoral immune response to leptospirosis infection will also be evaluated to determine whether they still get protective immunization. leptospirosis immunization will be evaluated using micro-agglutination test. graded immune responses related to the severity and the length of the infection will also be investigated. finally, 3 methods used for leptospirosis diagnosis will be compared. it is expected from this study to evaluate the appropriate conditions in which new vaccination could be required to prevent further leptospirosis infection in cured subjects.

Eligibility criteria:
inclusion criteria: * subjects diagnosed for leptospirosis by polymerase chain reaction measured in reunion island hospital between 209-2015 * with social security issue exclusion criteria: * leptospirosis diagnosis not confirmed by polymerase chain reaction * subject exhibiting immunodepressive status (cancers, transplantation, immune deficit, blood disorders) * under medication: corticoids, immunosuppressor, chemiotherapy
effect of met on meralgia paraesthesia postpartum "muscle energy technique"

Conditions: Meralgia Paresthetica; Femoral Neuropathy

Summary: to investigate the effect of muscle energy technique on femoral meralgia paraesthesia in a postpartum female. background: meralgia paraesthesia is one of the serious disorders in the postpartum female which results in pain and less physical activities. .........hypotheses: this study hypothesized that: muscle energy technique will have a significant effect on femoral meralgia paraesthesia in postpartum female

thirty meralgia paraesthesia postpartum females will participate in this study. the patients will randomly be divided into two equal groups; the control group received the conventional selected exercise program and the study group received the same exercise training program in addition to muscle energy technique, three times per week for four weeks. the evaluation methods by femoral nerve conduction velocity will be measured via the neuropack s1 meb9004 emg device before the exercise program and after finishing the exercise program, and also the pelvic compression test and pain numeric rating scale

Eligibility criteria:
inclusion criteria: * thirty meralgia paraesthesia postpartum female patients * with positive pelvic compression test * age ranging from 25:40 years * post vaginal delivery or post-operative (postpartum) persistent dysthesia in anterolateral thigh (one side or both) * body mass index (20:29.9) kg/m2 exclusion criteria: * difficulty to communicate or to understand program instructions * other conditions that caused pain (for example fibromyalgia and arthritis) * any psychiatric or cognitive symptoms any other musculoskeletal disorders or neurologic diseases of the lower extremities and spine
a validation study of mobile virtual reality-based self-care and exposure therapy contents for the treatment of panic disorder

Conditions: Panic Disorder

Summary: the purpose of this study is to determine whether mobile-based virtual reality exposure treatement can reduce the symptoms of panic disorder and the symptoms of depression and anxiety than the waitlist group


Eligibility criteria:
inclusion criteria: - meet diagnostic statistical manual criteria for panic disorder(with or without agoraphobia) . no change in drug dosage during the study period exclusion criteria: - patients with a history of major neurological or significant medical illness, or met the diagnostic criteria of current substance misuse
efficacy and safety of belimumab in sle patients

Conditions: Systemic Lupus Erythematosus

Summary: systemic lupus erythematosus (sle) is a chronic inflammatory systemic autoimmune disease. recurrent relapses of disease and development of long-term organ damage are two key unsolved clinical problems. belimumab is the only fda-approved biological agent for sle. data showed that treatment with belimumab on the background of standard therapy was effective in active sle patients. however, the efficacy of low-dose belimumab for prevention of disease flares in sle patients with low disease activity is to be explored.

systemic lupus erythematosus (sle) is a chronic systemic autoimmune disease with the incidence of about 70/100,000 in china. recurrent relapses of disease and development of long-term organ damage are two key unsolved clinical problems. its pathogenesis is still unclear, but b cells have been confirmed to play a vital role in it. belimumab, a b-lymphocyte stimulating factor (blys) inhibitor, was the only fda-approved biological agent for sle. bliss-52 showed that more active lupus patients had their selena-sledai score reduced by at least 4 points during 52 weeks with belimumab 10 mg/kg (58% vs 46%, p=0·0024) than with placebo. but there was limited data about belimumab in sle patients with low disease activity. our previous study indicated that even these patients still have an annual flare rate of 30-40%. therefore, we try to explore whether low-dose of belimumab could prevent the disease flares in sle patients with low disease activity.

Eligibility criteria:
inclusion criteria: 1. age 18-70 years; 2. patients with low disease activity (score≤ 6 at screening on sledai); no british isles lupus assessment group (bilag) a and no more than one b; 3. a stable treatment regimen with fixed doses of prednisone (≤ 20mg/day), antimalarial, or immunosuppressive drugs (azathioprine/mycophenolate mofetil/ methotrexate/ciclosporin/leflunomide/tacrolimus) for at least 30 days. 4. sign the informed consent; exclusion criteria: 1. alanine aminotransferase (alt)/ aspartate aminotransferase (ast) \> 2 times upper normal limits; 2. creatinine clearance rate \< 60ml/min; 3. exposure to cyclophosphamide within past 6 months before screening; 4. exposure to any b cell targeted therapy (rituximab/belimumab) within past 1 year before screening; 5. history of malignancy; 6. history of herpes zoster with past 3 months before screening. 7. chronic hbv/hcv hepatitis； 8. current infections (hiv/tuberculosis)

Keywords: belimumab systemic lupus erythematosus disease flare
information or physical activity for chronic lbp

Conditions: Low Back Pain

Summary: the purpose of this study is to compare a specific fear-reducing information with symptom-based exercise


Eligibility criteria:
inclusion criteria: * daily lbp, dominating over possible pain in leg or other joints/muscles * pain og \> 4 (scale 0-10) for more than 4 months exclusion criteria: * cancer, inflammatory disease, previous back surgery, pregnancy
aldosterone antagonism and microvascular function

Conditions: Abdominal Obesity Metabolic Syndrome; Insulin Resistance; Hypertension

Summary: the prevalence of obesity and obesity-related complications is currently taking epidemic proportions. these complications increase the risk of type 2 diabetes and cardiovascular disease, which are important causes of morbidity and mortality worldwide. it is important to gain insight in the mechanisms underlying obesity-related complications, because this may lead to the development of directed therapeutic strategies. currently, there is significant evidence that the cause of both insulin resistance and hypertension must be sought at the level of the microcirculation. over activity of the renin-angiotensin-aldosterone system is a potential cause of microvascular dysfunction. angiotensin ii was indeed found to be implicated in the pathogenesis of obesity-associated hypertension and insulin resistance, possibly through interference with the vascular effects of insulin. increased aldosterone levels have also been associated with resistant hypertension and insulin resistance, which is illustrated in patients with primary aldosteronism. furthermore, aldosterone is known to exert several detrimental effects on the vasculature, some of which are offset by mineralocorticoid receptor antagonists. in obese individuals, plasma aldosterone concentrations are increased as well. we hypothesize that increased aldosterone levels in adipose persons induce microvascular dysfunction, which contributes to the development of insulin resistance and hypertension, and mineralocorticoid receptor antagonism results in improved insulin sensitivity and decreased blood pressure by counteracting the adverse effects of aldosterone on the microvasculature.


Eligibility criteria:
inclusion criteria: * age 40-65 years * caucasian * waist circumference \> 102 cm (men)/\> 88 cm (women) * triglycerides \> 1.7 mmol/l * high-normal blood pressure (office blood pressure: 130/85 - 139/89 mm hg) or stage i hypertension (office blood pressure: 140/90 mm hg - 159/99 mm hg; 24h abpm: 125/80 - 149/89 mm hg) exclusion criteria: * cardiovascular disease (stroke, coronary artery disease, peripheral vascular disease, congestive heart failure, cardiac shunts, cardiac surgery, pulmonary hypertension, cardiac arrhythmias, family history of cardiac arrhythmias or sudden cardiac death) * diabetes mellitus/impaired glucose metabolism (fasting glucose values \> 5.6 mmol/l) * grade 2 or 3 hypertension (office blood pressure: \> 160/100 mm hg; abpm \> 150/90 mm hg) * unstable or severe pulmonary disease * unstable or severe thyroid disorders * inflammatory diseases * alcohol use \> 2 u/day (women)/\> 3 u/day (men) * use of antihypertensive, lipid-lowering or glucose-lowering medications, * use of corticosteroids, medication known to inhibit or induce cyp3a4, lithium, and tricyclic antidepressants or antipsychotic medication, and regular use (weekly or several times a week) of nsaids * plasma potassium levels \ 5 mmol/l * egfr \< 60 ml/min * impairment of hepatic function * pregnancy or lactation
intradermal acupuncture versus sham acupuncture and ssri for treating adolescents with major depressive disorder

Conditions: Major Depressive Disorder

Summary: major depressive disorder (mdd) is a prevalent mental illness characterised by influencing the health and quality of life of patients，often manifesting in individuals under the age of 18. it has been wildly confirmed that acupuncture alone or in combination with the applicable adjuvant therapy for mdd can not only relieve patients' physical symptoms, but also enhance sleep quality. intradermal acupuncture, as an acceptable and long-lasting treatment modality, is the focus of this research. this study was conducted to investigate the efficacy of intradermal acupuncture in the treatment of mdd.

this study will enroll a total of 120 adolescents with mdd who meet the inclusion criteria. participants will be randomly assigned 1:1:1 to the waiting list group (patients in this group will be treated with selective 5-hydroxytryptamine reuptake inhibitors (ssris) only), sham intradermal acupuncture combined with ssris (sia) group and active intradermal acupuncture combined with ssris (aia) group. the study is aim to evaluate the efficacy of intradermal acupuncture for mdd and examine whether intradermal acupuncture reduces side effects and improves the efficacy of ssris for mdd.

Eligibility criteria:
inclusion criteria: 1. patients diagnosed with mdd according to the international classification of disease-10 (icd-10); hamd-17≥7 2. aged between 12 and 17 years (no limitation on gender); 3. take ssri for at least two weeks; 4. written informed consent is obtained by the person or guardian. exclusion criteria: 1. icd-10 diagnoses: schizophrenia, bipolar disorder, manic episode or other psychotic disorders; alcohol and drug addiction; 2. significant skin lesions, severe allergic diseases, tumors, and severe or unstable internal diseases involving the cardiovascular, digestive, endocrine, or hematological system; 3. acute suicidal tendency; 4. allergy to adhesive tape and fear of intradermal acupuncture; 5. pregnancy and lactation; 6. mental retardation and difficult to cooperate with doctors. 7. participating in other clinical trials.

Keywords: major depressive disorder intradermal acupuncture randomized controlled trial adolescent